My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2008 Nov;31(11):2198-202. Epub 2008 Jul 23.PMID: 18650371 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.

    [No authors listed]

    Diabetes. 1996 Oct;45(10):1289-98.PMID: 8826962 [PubMed - indexed for MEDLINE]Related articles

    3.

    The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2006 Jul;29(7):1486-90.PMID: 16801566 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

    [No authors listed]

    Diabetes. 1997 Nov;46(11):1829-39.PMID: 9356033 [PubMed - indexed for MEDLINE]Related articles

    5.

    The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial.

    Lachin JM, Genuth S, Nathan DM, Rutledge BN.

    Diabetes. 2007 Jul;56(7):1913-21. Epub 2007 Mar 14.PMID: 17360979 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

    [No authors listed]

    N Engl J Med. 2000 Feb 10;342(6):381-9. Erratum in: N Engl J Med 2000 May 4;342(18):1376. PMID: 10666428 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

    [No authors listed]

    Diabetes. 1995 Aug;44(8):968-83.PMID: 7622004 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2009 Oct;32(10):1901-3. Epub 2009 Jun 23.PMID: 19549736 [PubMed - in process]Related articles

    9.

    Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.

    [No authors listed]

    Arch Ophthalmol. 1998 Jul;116(7):874-86. Erratum in: Arch Ophthalmol 1998 Nov;116(11):1469. PMID: 9682700 [PubMed - indexed for MEDLINE]Related articles

    10.

    Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes.

    McCarter RJ, Hempe JM, Gomez R, Chalew SA.

    Diabetes Care. 2004 Jun;27(6):1259-64.PMID: 15161772 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

    White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM.

    Arch Ophthalmol. 2008 Dec;126(12):1707-15.PMID: 19064853 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Predictors of abnormal cardiovascular autonomic function measured by frequence domain analysis of heart rate variability and conventional tests in patients with type 1 diabetes.

    Mäkimattila S, Schlenzka A, Mäntysaari M, Bergholm R, Summanen P, Saar P, Erkkilä H, Yki-Järvinen H.

    Diabetes Care. 2000 Nov;23(11):1686-93.PMID: 11092293 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

    [No authors listed]

    Ann Intern Med. 1998 Apr 1;128(7):517-23.PMID: 9518395 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.

    [No authors listed]

    Diabetes Care. 1999 Jan;22(1):99-111.PMID: 10333910 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Good glycemic control remains crucial in prevention of late diabetic complications--the Linköping Diabetes Complications Study.

    Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J.

    Pediatr Diabetes. 2009 May;10(3):168-76. Epub 2008 Oct 22.PMID: 19175900 [PubMed - indexed for MEDLINE]Related articles

    16.

    Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control.

    Zhang L, Krzentowski G, Albert A, Lefebvre PJ.

    Diabetes Care. 2001 Jul;24(7):1275-9.PMID: 11423515 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.

    Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group.

    Diabetes. 2005 Nov;54(11):3103-11.PMID: 16249432 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

    White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

    J Pediatr. 2001 Dec;139(6):804-12.PMID: 11743505 [PubMed - indexed for MEDLINE]Related articles

    19.

    Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.

    Genuth S.

    Endocr Pract. 2006 Jan-Feb;12 Suppl 1:34-41. Review.PMID: 16627378 [PubMed - indexed for MEDLINE]Related articles

    20.

    Glycemic control predicts diabetic extrarenal microvascular complications but not renal survival in patients with moderate to severe chronic kidney disease.

    Crook ED, Patel S.

    Ethn Dis. 2006 Autumn;16(4):865-71.PMID: 17061739 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity